Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
American Journal of Physiology. Cell Physiology|June 3, 2024
ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cellsVeronika Nemethova, Petra Babiakova, Boglarka Teglasova, et al.
International Journal of Nanomedicine|May 13, 2024
Long-Term Accumulation, Biological Effects and Toxicity of BSA-Coated Gold Nanoparticles in the Mouse Liver, Spleen, and KidneysKristina Jakic, Michal Selc, Filip Razga, et al.
The Journal of Clinical Investigation|July 19, 2005
The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophagesLiliana Schaefer, Andrea Babelova, Eva Kiss, et al.
Plos One|August 10, 2010
Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal diseaseOliver Jung, Felix Jansen, Anja Mieth, et al.
The Journal of Clinical Investigation|November 13, 2013
NADPH oxidase 4 limits bone mass by promoting osteoclastogenesisClaudia Goettsch, Andrea Babelova, Olivia Trummer, et al.
The American Journal of Pathology|April 6, 2010
Peroxisome proliferator-activated receptor (PPAR)gamma can inhibit chronic renal allograft damageEva Kiss, Zoran V Popovic, Jens Bedke, et al.
Bioconjugate Chemistry|September 8, 2016
Two-Step Mechanism of Cellular Uptake of Cationic Gold Nanoparticles Modified by (16-Mercaptohexadecyl)trimethylammonium BromideMonika Zarska, Filip Novotny, Filip Havel, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|November 11, 2019
Six-week inhalation of CdO nanoparticles in mice: The effects on immune response, oxidative stress, antioxidative defense, fibrotic response, and bonesJana Tulinska, Vlasta Masanova, Aurelia Liskova, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 29, 2022
Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer modelsVerona Buocikova, Eleonora Marta Longhin, Eleftherios Pilalis, et al.
Pageof 4